The International Federation of Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief ...

Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on ...

The Californian company earlier announced positive data at 52 weeks in a double-blind, dose-ranging Phase II study with ...

BRL Medicine raised $27 million in a Series B+ round, led by CSPC Fund, to advance its gene and cell therapies for genetic ...

Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with ...

Roche’s Phase III SKYSCRAPER-01 trial missed its primary endpoint, with tiragolumab combined with Tecentriq failing to ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

US central nervous system (CNS) disorders specialist Axsome Therapeutics (Nasdaq: AXSM) today released encouraging late-stage ...

Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money ...

All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and ...

South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with ...

Pyxis Oncology (Nasdaq: PYXS) has announced what look like encouraging early data from a Phase I trial of PYX-201, its lead ...